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Question: What are the mortality rates and key causes of excess mortality in people who use extra-
medical opioids?  
Findings: In this systematic review, people using extra-medical opioids died at ten times the rate of 
those of the same age and sex. Excess mortality occurs across traumatic causes of death, infectious 
diseases and non-communicable diseases.  
Meaning: Responses to elevated mortality in people using extra-medical must include overdose 
prevention, but also incorporate interventions to prevent and treat infectious diseases and non-





Importance: Extra-medical opioid use has escalated in recent years. A better understanding of cause-
specific mortality in this population is needed to inform comprehensive responses.  
Objective: Estimate all-cause and cause-specific crude mortality rates (CMR) and standardised 
mortality ratios (SMR) among people using extra-medical opioids, including age- and sex-specific 
estimates where possible. 
Data sources: Pubmed, PsycInfo and Embase were searched for studies published 2009-2018, and an 
earlier systematic review on this topic, published 2011.  
Study selection: We included cohort studies of people using extra-medical opioids and reporting 
mortality outcomes. Studies were screened for inclusion independently by two team members. We 
included 12426/8,602 683 studies (10097 primary studies and 240 studies providing additional data 
for primary studies).  
Data extraction and synthesis: Data were extracted by one team member and checked by another. 
Study quality was assessed using a custom set of items that examined risk of bias and quality of 
reporting. Data were pooled using random-effects meta-analysis models in STATA 15.1. 
Heterogeneity was assessed using stratified meta-analyses and meta-regression.  
Main outcomes and measures: All-cause and cause-specific CMRs and SMRs. The SMR measures the 
extent to which mortality is elevated relative to the general population of the same age and sex.   
Results: The pooled all-cause CMR, based on 997 cohorts including 1,262,592 people, was 1.67 per 
100 person-years (py; 95% confidence interval (CI) 1.45, 1.89), with substantial heterogeneity 
(I2=99.7%). Heterogeneity was associated with the proportion of the study sample that injected 
opioids or was living with HIV or hepatitis C. The pooled all-cause SMR, based on 432 cohorts, was 
10.09.9 (95% CI 7.65, 13.21). Excess mortality was observed across a range of causes, including 




Conclusions and relevance: People using extra-medical opioids experience significant excess 
mortality, much of which is preventable. The range of causes for which excess mortality was 
observed highlights the multiplicity of risk exposures experienced by this population, and the need 
for comprehensive responses that address these. There remains a need for better data on cause-






Extra-medical opioid use includes the use of heroin and other illicitly manufactured opioids, as well 
as the use of pharmaceutical opioids outside the bounds of a medical prescription.1 It is a significant 
public health problem in many countries globally,2 with use and related harms escalating across 
many high income countries.3 In the United States, HIV and hepatitis C virus (HCV) outbreaks 
associated with opioid injecting have been observed,4,5 and fatal opioid overdoses have increased 
dramatically, exceeding 47,000 deaths in 2018.6 Increasing trends sedin fatal opioid overdoses have 
also been observed in Canada, the United Kingdom, Australia, and Europe.7-10  
Overdose is not the only risk of extra-medical opioid use and injecting. In a previous systematic 
review, AIDS-related causes were at least as common as overdose deaths in six of 25 cohorts 
reporting both causes of death.11 More recently, increasing rates of HCV-related deaths have been 
observed in cohorts of people with a history of opioid dependence.12 Other elevated causes of death 
include suicide and other injuries.11  
Given the dynamic nature of extra-medical opioid use and related deaths, it is timely to review data 
on mortality rates and excess mortality among people who use extra-medical opioids, particularly 
cause-specific mortality. There is a need for data on cause-specific excess mortality to shed light on 
both overdose and non-overdose deaths in this population. We aimed to systematically review the 
literature to estimate all-cause and cause-specific crude mortality rates, standardised mortality 





Reporting of this review is in line with the MOOSE guidelines.13 The review protocol was registered 
with PROSPERO (registration number CRD42018094623). 
Search strategy and study selection 
A previous systematic review on this topic11 was used to identify studies published from 1980 to 
2008. Medline, Embase and PsycINFO databases were searched using the OVID interface/platform to 
identify relevant articles published from January 2009 until February 2018. An updated search was 
conducted to identify any recent relevant publications untilSearches were updated in October 2019.  
Search strings incorporating keywords and Medical Subject Headings (MeSH terms) reflecting drug 
type and mortality epidemiology were used and are provided in full in Appendix 1. No language 
restrictions were applied to the search, with the research team able to read in English, Italian, 
French, and Chinese. Studies in languages other than these were read using Google Translate.  
Study selection was completed using Covidence, a web-based systematic review management tool 
(https://www.covidence.org). Team members were trained in the requirements for inclusion of a 
study. Each retrieved citation was screened for inclusion based on title and abstract. All publications 
marked as excluded at this stage were reviewed by a second person and if there was a difference in 
the assessment, the publication was included for the next stage of the review All publications 
marked as excluded at this stage were reviewed by a second person who could overturn the initial 
exclusion decision. Each study included after initial screening was reviewed in full independently by 
two people. Disagreements were resolved through discussion between the two reviewers and 
referral to a third party if needed. Reference lists of reviews that were identified by the search were 
also screened to identify any additional publications.  
Inclusion and exclusion criteria 
We included cohort studies of people who use extra-medical opioids, recruited in any setting, that 




could include cohort studies of people who inject drugs, provided at least 90% of the cohort 
reported extra-medical opioid use. Cohorts did not need to be opioid dependent or have opioid use 
disorder to be included. Cohorts of people prescribed opioids for pain management or were 
exclusively people living with HIV or HCV were excluded, as were studies that reported case fatality 
rates only. Full inclusion and exclusion criteria are described in Appendix 2.  
Data extraction 
Data were extracted into a spreadsheet by one member of the research team and checked by 
anothera second member of the team. Extracted variables included study information (e.g. study 
country, years of data collection) and sample information (e.g. sex distribution, mean or median age, 
HIV and HCV status of participants) considered a priori to be potentially relevant to between-study 
heterogeneity. We extracted number of observed deaths, person-years of follow-up, and expected 
deaths to allow for calculation of CMRs and SMRs, but alsoand extracted CMRs and SMRs as 
reported. Specific causes for which data were extracted were overdose, AIDS-related, suicide, 
accidental injuries, homicide, liver disease, cardiovascular disease, respiratory disease, and cancer. 
When data for a study were incomplete, authors were contacted by email for additional 
information.  
During data extraction, it became apparent that there were inconsistencies were identified between 
studies in how overdose deaths were defined. Some studies stated only that they reported overdose 
mortality rates without explaining how overdose was defined. Where definitions were reported 
(typically using International Classification of Disease (ICD)-9 or ICD-10 codes), the most restrictive 
definitions included only opioid poisoning (n=6), while others included opioid and otherany drug 
poisoning (n=27). Less restrictive definitions included poisoning deaths as well as deaths attributed 
to mental and behavioural disorders due to psychoactive substance use (n=29). Pooled estimates 
were therefore calculated separately for the followingthree definitions of overdose death: opioid 




drug); and poisoning due to any drug and mental and behavioural disorders due to psychoactive 
substance use. Differences were also observed in how liver diseases were coded. We calculated 
pooled estimates for the following definitions: viral hepatitis (n=7); digestive diseases (including 
codes 520-579 in ICD-9 or Chapter XI of ICD-10; n=11); and liver-related (which typically included 
both of the previous categories, plus liver cancer; n=20). 
Study quality, including risk of bias 
As risk of bias tools for observational epidemiological studies are still evolving.,14 we developed a 
review-specific tool with close reference to two recent publications on assessing risk of bias in 
observational studies of exposures.14,15 The tool assessed each study on two risk of bias domains and 
three quality of reporting domains (Appendix 3). Risk of bias domains were sample 
representativeness and outcome measurement. Studies were rated as being at higher or lower risk 
of bias on each of these domains. Quality of reporting domains were completeness of reporting of 
cohort characteristics, completeness of outcome data, and reporting of definitions used for cause-
specific deaths. Studies were assessed as having higher or lower quality reporting on each of these 
domains. This information was used to add context regarding the validity of the findings. 
Data analysis 
CMRs were calculated as deaths per 100 person-years, and SMRs as observed deaths over expected 
deaths. We derived 95% confidence intervals for each metric using standard formulas (see Appendix 
4).  
SMRs represent the ratio of mortality risk among those exposed to the risk and the entire 
population, including those exposed to the risk. Relative risks (RRs) illustrate the ratio of mortality 
risk between those exposed to the risk and those not exposed to the risk. With a low prevalence 
exposure such as extra-medical opioid use, SMRs and RRs should be similar. We estimated RRs from 
SMRs by adjusting the SMR by the proportion of the general population that is exposed to the risk.16 




We explored heterogeneity through stratification and meta-regression and used random effects 
models for pooling data as we expected that there would be variation between the samples selected 
by the studies. For pooled analyses, wWe used used Stata 15.1 to complete DerSimonian and Laird 
Mantel-Haenszel random-effects meta-analyses in Stata 15.1. Study weights incorporated both 
within- and between-study error. to determine pooled all-cause and cause-specific CMR and SMR 
estimates. Random effects models were selected as we expected high levels of heterogeneity 
between cohorts. Heterogeneity was quantified using the I2 statistic. We took I2 of ≤25%, 25-≤50%, 
and >50% to indicate low, moderate and substantial heterogeneity, respectively.18  
We explored heterogeneity in the all-cause CMR and SMR through stratified meta-analyses and 
meta-regressions. Stratification variables for exploring heterogeneity included sex, age groups, year 
of completion of follow-up completion (with 1994 selected as the cut-point due to the introduction 
of highly active antiretroviral therapy for HIV in that year), injecting drug use status, opioid 
dependence/use disorder, recruitment setting (drug treatment or harm reduction settings compared 
to all other settings), and geographic region as defined by the Global Burden of Disease study. 
Depending on how data were presented, age groups were defined as <30 years compared to ≥30 
years, or <35 years compared to ≥35 years, and hereafter referred to as younger (<30 years and <35 
years pooled) compared to older (≥30 years and ≥35 years pooled). To increase the specificity of 
stratified estimates, Aall-cause and cause-specific CMR ratios comparing men and women, and 
younger and older people, were estimated. 
Each meta-regression included a single moderator variable, which could be a feature of the study 
sample (e.g. sex ratio; HIV prevalence) or a feature of the study design or conduct (e.g. sample size; 
recruitment setting). Variables were only included in meta-regressions if 5 or more data points were 
available. We took p<.05 to indicate an explanatory moderator variable that influenced 
heterogeneity in the CMR or SMR.  




Finally, weTo examined the distribution of causes of death across cohorts,. wWe identified the 
subset of cohorts where a cause was specified for all observed deaths (including that cause for x 
deaths was undetermined, as opposed to not reported or missing), and grouped deaths into the 
following categories: poisoning/substance dependence, infectious diseases, non-communicable 
diseases, trauma, and undetermined. In keeping with the way that cause-specific deaths were 
classifiedclassifications used in the included studies, deaths attributed to viral hepatitis were 
included in infectious diseases, but deaths attributed to liver disease were included in non-
communicable diseases, despite likely being sequelae of viral hepatitis infection. The weighted mean 
of the proportion of deaths in the cohorts due to each category was calculated, along with 95% 
confidence intervals based on a t distribution. Data on certain subordinate causes within a category 
were commonly reported, including AIDS-related deaths within infectious diseases; cancer and liver 
disease within non-communicable diseases; and suicide within trauma. Weighted means of the 






The PRISMA study flow diagram is shown in Figure 1. We included 124117 publications, including 
10097 primary publications and 240 secondary publications providing additional data for these 
primary publications. Cohorts were recruited from 28 countries, including 5 low- and middle-income 
countries (9 studies). Cohort size ranged from 10035 to 306,786 people and person-years of follow-
up ranged from 129 to 687,673. Characteristics of included studies are provided in Appendix 5.   
Risk of bias and study quality 
Just under half (43%) of the included cohorts were rated as being at higher risk of bias in relation to 
cohort representativeness (e.g. were recruited from a single site), and one quarter (24%) were at 
higher risk of bias relating to outcome measurement (e.g. mortality data derived from clinical 
records rather than death registries). Only 9% of cohorts did not report age and sex data to 
characterise the cohort sample. Just over a quarter (27%) of cohorts reported incomplete mortality 
data (i.e. missing either numerator or denominator), and 42% of the 80 cohorts reporting cause-
specific mortality did not report the definitions used to categorise deaths. A summary table and 
individual study assessments are provided in Appendix 6. 
All-cause mortality 
The pooled all-cause CMR, based on 997 cohorts, was 1.67 per 100 py (95% CI: 1.45, 1.89), with 
substantial heterogeneity (99.7%) (Table 1). Forest plots for this and all following pooled analyses 
are provided in Appendix 7.  The highest CMRs were observed in South Asia (7.6 per 100 py; 95% CI: 
4.8, 12.0; 2 cohorts, both from Bangladesh) and the lowest in Australasia (0.8 per 100 py; 95% CI: 
0.7, 1.0; 7 cohorts, all from Australia) (Table 1). 
In cohorts of people who injected opioids, the pooled all-cause CMR was 2.7 per 100 py (95% CI: 2.1, 
3.4) (Table 1). The prevalence of injecting drug use, HIV infection, and HCV infection within study 
samples were all important sources of heterogeneity and positively associated with higher CMRs 




CI: 1.3, 1.5), and among younger people compared to older people (CMR ratio 2.01.9, 95% CI: 1.65, 
2.53) (Table 3).  
The pooled all-cause SMR, based on 432 cohorts, was 10.09.9 (95% CI: 7.65, 13.21), with substantial 
heterogeneity (99.9%) (Table 1); among cohorts of people injecting opioids, the pooled all-cause 
SMR was 16.4 (95% CI: 10.9, 24.6) (Table 1). The highest pooled SMR was observed in Southeast Asia 
(13.4; 95% CI: 11.4, 15.3), and the lowest in North America (5.0; 95% CI: 4.2, 6.0). Excess mortality 
was more pronounced among women compared to men, and in younger people relative to older 
people (Table 3). Only the proportion of the cohort that injected drugs showed strong evidence of 
positive association with greater excess mortality (Table 2).  
Drug-related deaths 
There were 563 cohorts presenting data on drug-related deaths (Table 3). Across the three 
definitions for which data were extracted, the pooled CMR was 0.5 per 100 py (95% CI: 0.5, 0.6). 
Men had significantly higher drug-related mortality rates than women, as did older people relative 
to younger people (Table 3). Drug-related death was substantially elevated relative to the population 
(SMR 58.4; 95% CI: 38.1, 89.6) (Table 43 and Appendices 7 and 8).  Women and older people had 
higher drug-related SMRs than men and older people (Table 4 and Appendix 7).  
Traumatic deaths: Suicide, accidental injuries, and homicide  
Suicide and accidental injury deaths occurred at similar rates (pooled CMR for suicides and 
accidental injuries 0.1 per 100 py; 95% CI: 0.1, 0.2). The pooled CMR for suicide deaths was 0.1 per 
100 py (95% CI: 0.1, 0.2) (Table 3). Suicide deaths were more common among men than women 
(Table 3; pooled CMR ratio 1.87; 95% CI: 1.4, 2.2), and older people than younger people (Table 3; 
pooled CMR ratio 1.64; 95% CI: 1.1, 2.21.7). Suicide deaths occurred at almost more than 8 times the 
expected rate (Table 4; pooled SMR 7.98.5; 95% CI: 5.76.0, 11.012.1), and accidental injuries, seven 




violence was a relatively infrequent cause of death (pooled CMR 0.03 per 100 py; 95% CI: 0.02, 0.03) 
(Table 3), but occurred at more than 9 times the expected rate (pooled SMR 9.8; 95% CI: 6.6, 14.4) 
(Table 3).  
Accidental injury deaths occurred at a similar rate to suicides (Table 3; pooled CMR 0.1 per 100 py; 
95% CI: 0.1, 0.2), and were more common among men than women (Table 3; pooled CMR ratio 1.8; 
95% CI: 1.6, 2.1). The pooled accidental injury SMR was 6.9 (95% CI: 4.4, 10.6) (Table 4).  
Death from interpersonal violence was a relatively infrequent cause of death (pooled CMR 0.03 per 
100 py; 95% CI: 0.02, 0.03) (Table 3), but occurred at more than 9 times the expected rate (pooled 
SMR 9.8; 95% CI: 6.6, 14.4) (Table 4).  
AIDS-related deaths 
The pooled CMR for AIDS-related deaths was 0.2 per 100 py (95% CI 0.1, 0.3) (Table 3), and the 
pooled SMR was 18.5 (95% CI 8.2, 42.0) (Table 43). Excess mortality due to AIDS was particularly 
pronounced among women (pooled SMR 54.03.98; 95% CI 21.62, 134.73; Appendix 8).  
Liver-related deaths 
The overall CMR was 0.12 per 100 py (95% CI 0.1, 0.3) (Table 3), and liver-related deaths were more 
common among men relative to women (Table 3; pooled CMR ratio 1.7; 95% CI: 1.4, 2.1) and older 
people relative to younger people (Table 3; pooled CMR ratio 7.7, 95% CI: 5.8, 10.0). Liver-related 
deaths occurred at more than 8 times the expected rate (Table 43; pooled SMR 8.06, 95% CI: 6.51, 
9.912.1). 
Other disease deaths: Cardiovascular disease, cancer, and respiratory disease 
Studies reported mortality rates due to a range of non-communicable diseases, most 
commonly,Pooled CMRs were similar for cardiovascular disease (pooled CMR 0.1 per 100 py; 95% CI: 
0.1, 0.2), cancer (pooled CMR 0.1 per 100 py; 95% CI: 0.1, 0.2), and respiratory disease (including 




3). SMRs were elevated across all of these causes, particularly respiratory disease (pooled SMR 10.6; 
95% CI: 7.8, 14.4) (Table 43).  
Relative risks 
Relative risks of all-cause and cause-specific death were similar to the reported SMRs and are shown 
in Appendix 89.  
Distribution of causes of death  
There were 19 cohorts reporting a cause for all observed deaths that could be included in an the 
analysis of distribution of causes of death, mostly originating from Western Europe (see Appendix 9 
10 for included cohorts). Poisoning/substance-related (including alcohol-related) deaths were the 
most common cause, accounting for just under one-third of deaths (31.5%; 95% CI: 25.1%, 37.8%) 
(Figure 2). Non-communicable diseases accounted for one-quarter (24.1%; (95% CI: 17.1%, 31.2%) of 
deaths. Infectious diseases (19.7%; 95% CI: 11.7%, 27.8%) and traumatic deaths (18.1%; 95% CI: 






Globally, peoplePeople who use extra-medical opioids have had an elevated risk of mortality across 
several major causes of deaths, including cancer, cardiovascular disease and respiratorynon-
communicable diseases, as well as overdose, infectious diseases, and injuries. Variation in mortality 
between cohorts was driven by the prevalence of injecting drug use, HIV, and HCV within study 
cohorts. Most cohorts were recruited from multiple sites or used population-based registries 
covering a broad geographic area, and mortality was typically ascertained using official death 
registries, contributing to confidence in the findings. Relative to a previous systematic review of this 
question,11 we have highlighted the significant burden of mortality due to non-communicable 
diseases in this population, and provided sex- and age-specific estimates of cause-specific excess 
mortality. This high level of mortality across multiple causes of death highlights the range of risk 
exposures experienced by this population. For example, a high prevalence of smoking and oncogenic 
viruses such as HCV contribute to cancer deaths nearly three times as high as expected.  
Implications 
Addressing this burden of mortality requires a range of strategies to address different risk exposures. 
Opioid agonist treatment (OAT) significantly reduces mortality across a range of causes, including 
drug-related deaths, suicides, and injuries, but is often not accessible for many people who could 
benefit from treatment, even in high-income countries.19-21 In addition to reducing overdose and 
other mortality, increasing access to OAT can reduces HIV and HCV infections22,23 and criminal 
offendingcontact with the legal system,24 thereby generating broad public health and safety 
benefits.  
Although OAT is effective in reducing overdose, Iincreased access to naloxone in the community is 
also required to enable acute management of overdoses. Take-home naloxone programs are 
effective in reducing mortality among program participants,25 and emerging evidence suggests that 




Ongoing significant Eexcess mortality due to HIV and viral hepatitis points to the need to increase 
access to treatment for HIV and HCV infections. People who use and inject drugs have poor access to 
HIV antiretroviral therapies in many countries, largely as a result ofdue to socio-structural barriers 
such as policies or clinician preference to avoid treatment initiation in people who use drugs, and 
stigma and discrimination.27,28 HCV infection is endemic in people who inject drugs, reflected in 
elevated liver-related deaths.29 New highly effective, curative treatments for HCV infection should 
address this burden, but access to treatment is likely to remain an issue in many countries.30  
Smoking is highly prevalent among people who use extra-medical opioids,31 reflected here in excess 
mortality due to cardiovascular disease, respiratory disease, and cancer. Smoking cessation 
programs have been trialled in OAT settings, with nicotine replacement therapies being superior to 
placebo, and adjunctive behavioural therapies having no additional impact on abstinence at follow-
up.32 However, absolute rates of sustained smoking cessation are low.33 There is a need to improve 
access to and effectiveness of smoking cessation interventions in this population.33  
In terms of structural factors potentially associated with all-cause mortality, in meta-regression 
analyses neither homelessness nor past incarceration appeared to be important variables. However, 
there were few studies (n=7) reporting on homelessness in their samples, and extreme excess 
mortality across all causes has frequently been observed in people who are unsheltered,34 with 
overdose, suicide and other unnatural deaths particularly increased relative to housed populations.35 
Much of the work on homelessness and mortality has been undertaken with the wider population of 
people who are homeless. In light of the current overdose crisis, there is a need for evidence on the 
role of housing in mortality overdose incidence and outcomes specifically in people using extra-
medical opioids, particularly associations between access to housing and overdose mortality rates. 
There were also few (n=14) studies reporting  incarceration history in their samples, and 




increases overdose mortality risk,36 better characterisation of recent incarceration is essential for 
better understanding its impact on mortality in this population.   
Limitations of included studies 
A key limitation of included cohorts was missingwas lack of information on how specific causes of 
death were defined. Of the 80 cohorts with cause-specific mortality rates, 34 did not report how 
specific causes were defined. Of those with definitions, there was significant variation between 
studies in defining drug- and opioid-related deaths. Consistency in defining drug- and opioid-related 
deaths is critical to ensuring accurate monitoring and assessing progress towards reducing drug-
related deaths across and within countries. Liver-related deaths were another broad area where 
inconsistencies were identified. Clarification and increasing consistency of the codes included in this 
category would assist in enabling monitoring of HCV elimination andthe public health impacts of 
HCV antiviral therapies.   
A previous systematic review on this topic noted thatidentified very little data from low- and middle-
income countries had been identified.11 There have been only minor increases in data from low- and 
middle-income countries in this review, and there remain several world regions (e.g. Latin America 
and the Caribbean, Sub-Saharan Africa) with no relevant data on excess mortality in people using 
extra-medical opioids. Such data are needed to, for example, determine need for overdose 
prevention programs, and assess access to HIV antiretroviral therapy among people who use drugs.   
Limitations of this review 
Despite a comprehensive search strategy including reports in any language, it is possible we did not 
identify some cohorts. There were limited age- and sex-specific CMRs and SMRs for several key 
causes of death, which is a concern given changes in dominant causes of death across the lifespan 
for people using extra-medical opioids.37 We did not seek to determine mortality rates in relation to 




Their That review confirmed that OAT with either methadone or buprenorphine is highly protective 
against death, although there are periods of elevated mortality risk during methadone induction and 
after treatment cessation.38 We were unable to explore heterogeneity in cause-specific deaths 
associated with country or region of origin due to small numbers of studies for most causes.      
This review related specifically to people using, injecting, and/or seeking treatment for their use of 
extra-medical opioids such as heroin. Our definitionWe did not exclude people with infrequent or 
non-disordered extra-medical opioid use, which may have contributed to heterogeneity in our 
estimates. However, the CMR limited to cohorts defined as opioid dependent cohorts was similar to 
the overall CMR, suggesting that this definition did not substantially impact on the results. 
Notwithstanding that in some settings there is considerable overlap between people using illicit 
opioids and people using extra-medical pharmaceutical opioids, we do not consider that the results 
presented here apply to people who are prescribed opioids and not engaging in extra-medical opioid 
use.. A separate review of mortality in that population reported a higher pooled all-cause CMR (2.4 
per 100 py; 95% CI: 0.9, 6.2) relative to this study, likely due to the substantially older age profile of 
the included samples. The pooled overdose CMR in people prescribed opioids was low (0.06 per 100 
py; 95% CI 0.02, 0.2). 
Conclusions 
People who use extra-medical opioids experience a high burden of excess mortality across a range of 
causes. Combinations of evidence-based interventions to reduce mortality will have significantly 
greater impact than single interventions.39 Combinations of OAT, needle and syringe programmes, 
and naloxone as well as treatment for HIV and HCV infections will have synergistic impacts in 
reducing overdose, disease incidence, and mortality due to multiple adverse health outcomes. There 
is an urgent need to scale up combination interventions across myriad health issues to ensure that 
people who use opioids no longer face elevated mortality risks for health outcomes for which 




easily available to the wider community. These findings reinforce the need for widely available OAT; 
increased access to naloxone among people using opioids and their social networks; and increased 
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Table 1: Pooled all-cause crude mortality rates among people using extra-medical opioids, by sex, age group, drug use characteristics, and region 
 Crude mortality rates Standardised mortality ratios 
Strata N cohorts Pooled crude mortality 
rate per 100PY (95%CI) 
I2 N cohorts Pooled standardised 
mortality ratio (95%CI) 
I2 
All-cause mortality 991 1.59 (1.40-1.80) 99.7% 43 10.03 (7.64-13.17) 99.9% 
Sex       
Men  47 1.85 (1.51-2.27) 99.7% 31 8.56 (6.70-10.93) 99.9% 
Women 43 1.28 (1.03-1.58) 99.4% 30 13.40 (8.90-20.16) 99.9% 
Age2       
Younger 18 1.25 (0.91-1.71) 99.5% 5 10.96 (4.59-26.16) 99.8% 
Older 18 2.09 (1.51-2.91) 99.9% 5 5.24 (4.53-6.05) 94.6% 
Follow up completed       
      By end of 1994 7 1.85 (0.97-3.55) 99.8% 4 9.33 (4.98-17.46) 99.4% 
      Continued or commenced in 1995 or later 90 1.57 (1.39-1.78) 99.6% 39 10.10 (7.56-13.50) 99.9% 
Injecting cohorts3 19 2.71 (2.14-3.42) 95.2% 10 16.37 (10.92-24.55) 98.8% 
Dependent cohorts4 67 1.54 (1.33-1.78) 99.7% 36 10.31 (7.63-13.93) 99.9% 
Recruitment setting       
   Drug treatment or harm reduction setting 57 1.58 (1.37-1.82) 99.5% 29 10.25 (7.78-13.51) 99.8% 
   Other settings5 40 1.60 (1.31-1.96) 99.7% 14 9.42 (7.74-11.46) 99.5% 
GBD region6       
Australasia 7 0.80 (0.67-0.96) 91.3% 3 8.63 (6.49-11.47) 93.2% 
East Asia 6 1.80 (1.37-2.35) 96.7% 4 9.89 (6.15-15.92) 98.2% 
Southeast Asia 3 4.53 (3.11-6.62) 69.3% 1 13.40 (11.40-15.30) - 
South Asia 2 7.62 (4.84-12.00) 60.9% - - - 
North Africa & Middle East 2 3.40 (0.97-11.87) 95.2% - - - 
Central Europe 3 1.17 (0.61-2.23) 96.2% 1 12.06 (9.60-15.00) - 
Western Europe 54 1.56 (1.32-1.84) 99.5% 27 11.87 (9.15-15.40) 99.8% 
North America 20 1.61 (1.36-1.91) 99.5% 7 5.02 (4.21-5.98) 99.2% 
1Includes two studies40,41 that reported no deaths and therefore not shown in the forest plots. 2Studies presented age-specific data using various age groups; this analysis 
includes studies where the age groups could be summarised as < 30 years vs ≥ 30 years or < 35 years vs ≥ 35 years. 3Includes only cohorts defined by opioid injecting. 
4Includes only cohorts defined by opioid dependence or opioid use disorder. 5Other settings include acute care (e.g. emergency departments), prisons and community 
settings. 6Regions are defined as per the Global Burden of Disease (GBD) project. No studies were found for the following GBD regions: Latin America and the Caribbean; 




Table 2: Meta-regression of potential sources of heterogeneity in the pooled all-cause crude mortality rate and standardised mortality ratio 
 Crude mortality rate  Standardised mortality ratio  
 N studies Coefficient (SE) Adj. R2 P N studies Coefficient (SE) Adj. R2 P 
Cohort characteristics at baseline         
% injecting 43 4.297 (1.818) 22.67% 0.001 16 7.592 (4.725) 43.41% 0.006 
% male 76 2.316 (1.745) -0.26% 0.269 30 2.305 (2.908)   -1.89% 0.514 
Mean/median age  42 1.000 (0.022) -2.65% 0.991 19 0.953 (0.027) 10.97% 0.101 
% HIV positive 23 13.569 (12.041) 27.68% 0.008 10 107.159 (270.897) 21.99% 0.102 
% HCV Positive 19 4.134 (2.478) 19.73% 0.030 6 12.924 (19.898) 27.35% 0.172 
% history of homelessness 8 11.081 (20.865) 7.24% 0.249 3 0.000 (0.000) 91.52% 0.160 
% history of incarceration 16 0.736 (0.399) -4.11% 0.580 6 0.674 (0.514) -19.27% 0.632 
Study characteristics         
Year of follow-up completion         
   Follow-up completed by end of 1994 7 - - - 4 - - - 
   Follow-up continued or commenced ≥1995 90 0.851 (0.266) -0.91% 0.606 39 1.058 (0.384) -2.55% 0.878 
Sample size 95 1.000 (0.000)  -0.19% 0.391 41 1.000 (0.000) 7.74% 0.051 
Person-years of follow-up 96 1.000 (0.000)  0.66% 0.249 39 1.000 (0.000) 6.43% 0.074 
Recruitment setting         
   Drug treatment or harm reduction setting  57 - - - 29 - - - 
   Other settings1 40 -0.023 (0.167) -1.25% 0.891 14 0.927 (0.209) -2.27% 0.737 





Table 3: Pooled all-cause and cause-specific CMRs among people using extra-medical opioids, pooled CMR ratios comparing men and women, and older 
and younger people, and pooled all-cause and cause-specific SMRs  












ratio (95% CI) 
I2 N 
cohorts 
Pooled SMR (95%CI) I2 
All-cause 99 1.59 (1.40-1.80) 99.7% 45 1.38 (1.30, 1.47) 84.0% 10 1.98 (1.59, 2.47) 97.5% 43 10.03 (7.64-13.17) 99.9% 
Drug-related 56 0.52 (0.46-0.59) 98.3% 15 1.44 (1.27, 1.64) 71.4% 8 1.19 (0.94, 1.50) 87.6% 12 58.43 (38.09-89.64) 99.7% 
   Opioid 
poisoning    






1 2.84 (2.50, 3.23) 
 
- 1 43.50 (41.40-45.80) - 
   Drug poisoning 30 0.44 (0.36-0.53) 97.7% 7 
 








6 63.33 (31.31-128.08) 98.4% 
   Poisoning and 
disorders due to 
psychoactive 
substance use 
28 0.50 (0.43-0.59) 98.3% 9 1.39 (1.20, 1.61) 80.3% 4 1.31 (1.02, 1.69) 91.1% 6 60.42 (31.81-114.76) 99.8% 
Suicide 36 0.12 (0.10-0.16) 96.1% 10 1.78 (1.42, 2.24) 30.3% 4 1.57 (1.14, 2.17) 63.0% 10 7.93 (5.69-11.04) 97.1% 
Accidental injury 29 0.14 (0.10-0.18) 97.4% 7 1.82 (1.61, 2.07) 0.0% 1 0.99 (0.65, 1.51) - 8 6.85 (4.41-10.64) 98.2% 
Violence 19 0.03 (0.02-0.03) 70.8% 4 1.68 (0.76, 3.72) 66.8% 3 1.15 (0.65, 2.05) 64.9% 8 9.75 (6.60-14.39) 81.8% 
AIDS-related 36 0.19 (0.12-0.28) 99.3% 7 1.35 (0.70, 2.60) 97.1% 1 2.31 (0.47, 
11.44) 
- 5 18.50 (8.15-41.99) 99.1% 
Liver 33 0.14 (0.08-0.27) 99.8% 6 1.69 (1.38, 2.07) 8.5% 3 8.00 (6.45, 9.92) 0.0% 11 8.60 (6.13-12.07) 96.4% 
   Viral hepatitis 7 0.13 (0.01-1.10) 99.9% 3 1.42 (0.80, 2.54) 65.5% 0 - - 4 35.94 (16.06-80.42) 98.3% 
   Digestive 
diseases 
13 0.06 (0.04-0.10) 97.7% 2 1.43 (0.77, 2.68) 66.5% 2 7.94 (6.38, 9.87) 0.0% 7 7.00 (4.45-11.00) 96.2% 
   Liver-related 20 0.16 (0.08-0.35) 99.8% 5 1.63 (1.29, 2.07) 20.5% 3 8.64 (6.79, 
11.00) 
0.0% 6 6.58 (3.62-11.95) 98.6% 
Cardiovascular 30 0.14 (0.10-0.19) 99.1% 7 0.95 (0.87, 1.03) 1.7% 3 7.82 (4.06, 
15.08) 
83.2% 6 4.45 (2.97-6.66) 97.8% 
Cancer 31 0.12 (0.08-0.18) 99.3% 6 1.03 (0.79, 1.34) 55.0% 3 11.51 (4.71, 
28.13) 
86.9% 8 2.69 (1.84-3.92) 97.8% 
Respiratory 24 0.08 (0.06-0.12) 98.1% 3 0.65 (0.58, 0.73) 0.0% 2 14.09 (3.05, 
65.13) 




Figure 1: PRISMA flow diagram of studies of mortality in people using extra-medical opioids 
Figure 2: Distribution of causes of death in cohorts of people using extra-medical opioids (n=19 
cohorts) 
 
